Skip to main content

Advertisement

SpringerLink
Log in

Fertility preservation with ovarian stimulation and time to treatment in women with stage II–III breast cancer receiving neoadjuvant therapy

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

An Erratum to this article was published on 28 June 2017

This article has been updated

Abstract

Purpose

To determine whether fertility preservation with ovarian stimulation (OS) results in treatment delay in breast cancer (BC) patients receiving neoadjuvant therapy (NAT).

Methods

This is a retrospective study of women screened for the prospective neoadjuvant ISPY2 trial at the University of California San Francisco. All patients were <43, had stage II–III BC, and received neoadjuvant therapy. Time to initiation of NAT was compared between women who underwent OS (STIM) and women who did not (control). Patient and tumor characteristics, as well as oncologic outcomes, were compared between STIM and control groups.

Results

82 patients were included (34 STIM and 48 control). STIM patients were overall younger (mean = 35 vs. 36.9 years old, p = 0.06), and more likely to be childless (79.4 vs 31.2%, p < 0.0001) than controls. Mean time from diagnosis to initiation of NAT was 40 days, with no significant difference between STIM and control groups (mean 39.8 days vs 40.9 days, p = 0.75). Mean time from diagnosis to fertility consultation was 16.3 days. With median follow-up of 79 months, 16 (19.5%) patients have recurred or died from BC. Rates of pCR, recurrence, and death were similar in both groups. Six of 34 STIM patients have undergone embryo transfer, resulting in one patient with two live births.

Conclusion

Fertility preservation with OS can be performed in the neoadjuvant setting without delay in initiation of systemic therapy and should be discussed with all early-stage BC patients of reproductive age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

  • 28 June 2017

    An erratum to this article has been published.

References

  1. Trivers KF, Fink AK, Partridge AH, Oktay K, Ginsburg ES, Li C, Pollack LA (2014) Estimates of young breast cancer survivors at risk for infertility in the U.S. Oncologist 19(8):814–822. doi:10.1634/theoncologist.2014-0016

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mathews TJ, Hamilton BE (2016) Mean age of mothers is on the rise: United States, 2000-2014. NCHS Data Brief 232:1–8

    Google Scholar 

  3. Duffy CM, Allen SM, Clark MA (2005) Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 23(4):766–773. doi:10.1200/JCO.2005.01.134

    Article  PubMed  Google Scholar 

  4. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104(5):386–405. doi:10.1093/jnci/djr541

    Article  PubMed  Google Scholar 

  5. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer EP (2004) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22(20):4174–4183. doi:10.1200/JCO.2004.01.159

    Article  PubMed  Google Scholar 

  6. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R (2007) The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 30(2):126–132. doi:10.1097/01.coc.0000251398.57630.4f

    Article  CAS  PubMed  Google Scholar 

  7. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L, Group GIMS (2015) Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. Jama 314(24):2632–2640. doi:10.1001/jama.2015.17291

    Article  CAS  PubMed  Google Scholar 

  8. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS, Investigators PS (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372(10):923–932. doi:10.1056/NEJMoa1413204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K, American Society of Clinical O (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510. doi:10.1200/JCO.2013.49.2678

    Article  PubMed  PubMed Central  Google Scholar 

  10. Azim AA, Costantini-Ferrando M, Oktay K (2008) Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 26(16):2630–2635. doi:10.1200/JCO.2007.14.8700

    Article  CAS  PubMed  Google Scholar 

  11. Baynosa J, Westphal LM, Madrigrano A, Wapnir I (2009) Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg 209(5):603–607. doi:10.1016/j.jamcollsurg.2009.08.006

    Article  PubMed  Google Scholar 

  12. Kim J, Turan V, Oktay K (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 101(4):1364–1371. doi:10.1210/jc.2015-3878

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26(5):778–785. doi:10.1200/JCO.2007.15.0235

    Article  PubMed  Google Scholar 

  14. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7):2483–2493. doi:10.1200/JCO.1997.15.7.2483

    Article  CAS  PubMed  Google Scholar 

  15. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8

    Article  PubMed  Google Scholar 

  16. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281. doi:10.1200/JCO.2007.14.4147

    Article  PubMed  Google Scholar 

  17. Park JW, Liu MC, Yee D, Yau C, van’t Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, Investigators IS (2016) Adaptive randomization of neratinib in early breast cancer. N Engl J Med 375(1):11–22. doi:10.1056/NEJMoa1513750

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Rugo HS, Olopade OI, DeMichele A, Yau C, van’t Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, Investigators IS (2016) Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 375(1):23–34. doi:10.1056/NEJMoa1513749

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA (1982) Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 2(2):163–169

    Article  CAS  PubMed  Google Scholar 

  20. Cold S, During M, Ewertz M, Knoop A, Moller S (2005) Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer 93(6):627–632. doi:10.1038/sj.bjc.6602734

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jara Sanchez C, Ruiz A, Martin M, Anton A, Munarriz B, Plazaola A, Schneider J, del Prado PM, Alba E, Fernandez-Aramburo A (2007) Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat 101(2):215–223. doi:10.1007/s10549-006-9282-0

    Article  PubMed  Google Scholar 

  22. Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A (2005) Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 23(9):1934–1940. doi:10.1200/JCO.2005.04.032

    Article  PubMed  Google Scholar 

  23. Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735–744. doi:10.1200/JCO.2013.49.7693

    Article  PubMed  Google Scholar 

  24. Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH (2016) Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2(3):322–329. doi:10.1001/jamaoncol.2015.3856

    Article  PubMed  Google Scholar 

  25. Engel J, Eckel R, Kerr J, Schmidt M, Furstenberger G, Richter R, Sauer H, Senn HJ, Holzel D (2003) The process of metastasisation for breast cancer. Eur J Cancer 39(12):1794–1806

    Article  CAS  PubMed  Google Scholar 

  26. Folkman J (1990) Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev 9(3):171–174

    Article  CAS  PubMed  Google Scholar 

  27. Sanford RA LX, Giordano SH, Tripathy D, Barcenas CH, Chavez-Mac Gregor M (2016) Impact of delayed neoadjuvant systemic chemotherapy on survival outcomes in breast cancer patients. J Clin Oncol 34(suppl):abstr 1038

  28. Sonmezer M, Turkcuoglu I, Coskun U, Oktay K (2011) Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 95(6):2125-e2129. doi:10.1016/j.fertnstert.2011.01.030

    Article  Google Scholar 

  29. Cakmak H, Rosen MP (2015) Random-start ovarian stimulation in patients with cancer. Curr Opin Obstet Gynecol 27(3):215–221. doi:10.1097/GCO.0000000000000180

    Article  PubMed  Google Scholar 

  30. Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP (2017) Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. doi:10.1093/humrep/dew355

    PubMed  Google Scholar 

  31. Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F (2015) Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 33(22):2424–2429. doi:10.1200/JCO.2014.59.3723

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St., Box 1710, San Francisco, CA, 94115, USA

    A. Jo Chien, Fiona Mcauley, Jimmy Hwang, Mi-Ok Kim, Michelle E. Melisko, Hope S. Rugo & Laura J. Esserman

  2. University of California San Francisco School of Medicine, Francisco, CA, USA

    Julia Chambers

  3. Columbia University College of Physicians and Surgeons, New York, NY, USA

    Tessa Kaplan

  4. Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA

    Joseph Letourneau & Mitchell P. Rosen

Authors
  1. A. Jo Chien
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Chambers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fiona Mcauley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tessa Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joseph Letourneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jimmy Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mi-Ok Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michelle E. Melisko
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hope S. Rugo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Laura J. Esserman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mitchell P. Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Jo Chien.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Research involving human rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

The original version of this article was revised: The first author’s given and family names were swapped erroneously. The first author’s name is updated in the article.

An erratum to this article is available at https://doi.org/10.1007/s10549-017-4350-1.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chien, A., Chambers, J., Mcauley, F. et al. Fertility preservation with ovarian stimulation and time to treatment in women with stage II–III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat 165, 151–159 (2017). https://doi.org/10.1007/s10549-017-4288-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4288-3

Keywords

Search

Navigation